Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009–2014

Alimentary Pharmacology and Therapeutics

Volumn 45, Issue 1, 2017, Pages 37-49

  Kirchgesner, J ^a,b   Lemaitre, M ^a   Rudnichi, A ^a   Racine, A ^c   Zureik, M ^a   Carbonnel, F ^c   Dray Spira, R ^a  

^a Department of Epidemiology of Health Products   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MERCAPTOPURINE; TUMOR NECROSIS FACTOR INHIBITOR; GASTROINTESTINAL AGENT; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ABDOMINAL SURGERY; ADULT; ARTICLE; COLON RESECTION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFICACY; EARLY INTERVENTION; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE RESECTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; ULCERATIVE COLITIS; ADMINISTRATIVE CLAIMS (HEALTH CARE); ANTAGONISTS AND INHIBITORS; COLITIS, ULCERATIVE; DISEASE MANAGEMENT; FACTUAL DATABASE; FOLLOW UP; HOSPITALIZATION; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; TIME FACTOR; TRENDS;

ADMINISTRATIVE CLAIMS, HEALTHCARE; ADULT; COLITIS, ULCERATIVE; CROHN DISEASE; DATABASES, FACTUAL; DISEASE MANAGEMENT; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HOSPITALIZATION; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84996969420     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13835     Document Type: Article

References (38)

1. Dignass A, van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010; 4: 28–62.
2. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: current management. J Crohns Colitis 2012; 6: 991–1030.
3. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60: 571–607.
4. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383–95.
5. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014; 146: 392–400. e3.
6. Toruner M, Loftus EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929–36.
7. Schneeweiss S, Korzenik J, Solomon DH, et al. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther 2009; 30: 253–64.
8. Ananthakrishnan AN, Cagan A, Cai T, et al. Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2015; 41: 1141–8.
9. Nyboe Andersen N, Pasternak B, Friis-Møller N, et al. Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study. BMJ 2015; 350: h2809.
10. Beaugerie L, Itzkowitz S. Cancers complicating inflammatory bowel disease. N Engl J Med 2015; 372: 1441–52.
11. van der Valk ME, Mangen M-JJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut 2014; 63: 72–9.
12. Torres J, Boyapati RK, Kennedy NA, et al. Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease. Gastroenterology 2015; 149: 1716–30.
13. Pariente B, Laharie D. Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2014; 40: 338–53.
14. Rungoe C, Langholz E, Andersson M, et al. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011. Gut 2014; 63: 1607–16.
15. Burisch J, Pedersen N, Cukovic-Cavka S, et al. Initial disease course and treatment in an inflammatory bowel disease inception cohort in Europe: the ECCO-EpiCom cohort. Inflamm Bowel Dis 2014; 20: 36–46.
16. Vegh Z, Burisch J, Pedersen N, et al. Treatment steps, surgery, and hospitalization rates during the first year of follow-up in patients with inflammatory bowel diseases from the 2011 ECCO-Epicom inception cohort. J Crohns Colitis 2015; 9: 747–53.
17. Vester-Andersen MK, Prosberg MV, Jess T, et al. Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy. Am J Gastroenterol 2014; 109: 705–14.
18. Chantry AA, Deneux-Tharaux C, Cans C, et al. Hospital discharge data can be used for monitoring procedures and intensive care related to severe maternal morbidity. J Clin Epidemiol 2011; 64: 1014–22.
19. Sahli L, Lapeyre-Mestre M, Derumeaux H, et al. Positive predictive values of selected hospital discharge diagnoses to identify infections responsible for hospitalization in the French national hospital database. Pharmacoepidemiol Drug Saf 2016; 25: 785–9.
20. Lorgis L, Cottenet J, Molins G, et al. Outcomes after acute myocardial infarction in HIV-infected patients analysis of data from a French Nationwide Hospital Medical Information Database. Circulation 2013; 127: 1767–74.
21. Basson M, Mezzarobba M, Weill A, et al. Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study. Gut 2016; 65: 1664–9.
22. Bouillon K, Bertrand M, Maura G, et al. Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study. Lancet Haematol 2015; 2: e150–9.
23. Raguideau F, Lemaitre M, Dray-Spira R, et al. Association between oral fluoroquinolone use and retinal detachment. JAMA Ophthalmol 2016; 134: 415–21.
24. Weill A, Dalichampt M, Raguideau F, et al. Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study. BMJ 2016; 353: i2002.
25. Tuppin P, de Roquefeuil L, Weill A, et al. French national health insurance information system and the permanent beneficiaries sample. Rev DÉpidémiologie Santé Publique 2010; 58: 286–90.
26. Legifrance. Code de la santé publique - Article R5123-2. Available at: http://www.legifrance.gouv.fr
27. Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2014; 8: 443–68.
28. Annese V, Beaugerie L, Egan L, et al. European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohns Colitis 2015; 9: 945–65.
29. Swoger JM, Regueiro M. Stopping, continuing, or restarting immunomodulators and biologics when an infection or malignancy develops. Inflamm Bowel Dis 2014; 20: 926–35.
30. Khanna R, Bressler B, Levesque BG, et al. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. The Lancet 2015; 386: 1825–34.
31. Fidder HH, Singendonk MMJ, van der Have M, et al. Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review. World J Gastroenterol 2013; 19: 4344–50.
32. Treton X, Bouhnik Y, Mary J-Y, et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 2009; 7: 80–5.
33. Kennedy NA, Kalla R, Warner B, et al. Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. Aliment Pharmacol Ther 2014; 40: 1313–23.
34. Kennedy NA, Warner B, Johnston EL, et al. Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis. Aliment Pharmacol Ther 2016; 43: 910–23.
35. Vester-Andersen MK, Vind I, Prosberg MV, et al. Hospitalisation, surgical and medical recurrence rates in inflammatory bowel disease 2003-2011—a Danish population-based cohort study. J Crohns Colitis 2014; 8: 1675–83.
36. Odes S, Vardi H, Friger M, et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology 2006; 131: 719–28.
37. Sonnenberg A. Age distribution of IBD hospitalization. Inflamm Bowel Dis 2010; 16: 452–7.
38. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46–54.e42.